Evidence map›Paper›PMID 34411141›Full record

ArticlePloS one2021

The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.

Milad J Alasady, Alexander R Terry, Adam D Pierce, Michael C Cavalier, Catherine S Blaha, Kaylin A Adipietro, Paul T Wilder, David J Weber, Nissim Hay

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Milad J AlasadyDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Alexander R TerryDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL USA.ORCID 0000-0003-4731-8537
Adam D PierceDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Michael C CavalierDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Catherine S BlahaDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL USA.
Kaylin A AdipietroDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Paul T WilderDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
David J WeberDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Nissim HayDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL USA.ORCID 0000-0002-6245-3000
University of Maryland, Baltimore · USUniversity of Illinois Chicago · US

Funding

Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Restoration of Tumor Suppression Activity in Malignant MelanomaR01CA107331 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBER, DAVID JOSEPH · 2006 to 2015
$5.4M
Signal Propagation in Protein Allostery: Mechanism and EvolutionR01GM129327 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI WEBER, DAVID JOSEPH · 2019 to 2022
$1.3M
Exploiting Metabolic Changes in HCC for Cancer TherapyF30CA225058 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI TERRY, ALEXANDER RICHARD · 2018 to 2022
$241k
Elucidating the Mechanisms by which Hexokinase 2 Regulates Breast Cancer MetastasisF30CA228191 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BLAHA, CATHERINE · 2018 to 2021
$195k
NCI NIH HHS F30 CA225058NCI NIH HHS F30 CA228191NCI NIH HHS R01 CA107331NCI NIH HHS T32 CA154274NIGMS NIH HHS R01 GM129327
6 · The paper itself

Abstract

S100B is frequently elevated in malignant melanoma. A regulatory mechanism was uncovered here in which elevated S100B lowers mRNA and secreted protein levels of interleukin-6 (IL6) and inhibits an autocrine loop whereby IL6 activates STAT3 signaling. Our results showed that S100B affects IL6 expression transcriptionally. S100B was shown to form a calcium-dependent protein complex with the p90 ribosomal S6 kinase (RSK), which in turn sequesters RSK into the cytoplasm. Consistently, S100B inhibition was found to restore phosphorylation of a nuclear located RSK substrate, CREB, which is a potent transcription factor for IL6 expression. Thus, elevated S100B reduces IL6-STAT3 signaling via RSK signaling pathway in malignant melanoma. Indeed, the elevated S100B levels in malignant melanoma cell lines correspond to low levels of IL6 and p-STAT3.

Indexed as

Calcium-Binding ProteinsCell Line, TumorCyclic AMP Response Element-Binding ProteinCytoplasmDoxycyclineGene Expression Regulation, NeoplasticHumansInterleukin-6MelanomaRibosomal Protein S6 Kinases, 90-kDaS100 Calcium Binding Protein beta SubunitSignal TransductionSTAT3 Transcription FactorCalcium-Binding ProteinsCREB1 protein, humanCyclic AMP Response Element-Binding ProteinDoxycyclineInterleukin-6Ribosomal Protein S6 Kinases, 90-kDaS100B protein, humanS100 Calcium Binding Protein beta SubunitSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID34411141
PMCPMC8376063
OpenAlexW3195820473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.